tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ELVN Stock Latest News

Enliven Therapeutics: Robust ELVN-001 CML Data, Clear Pivotal Path, and Solid Cash Runway Support Buy Rating
RatingsEnliven Therapeutics: Robust ELVN-001 CML Data, Clear Pivotal Path, and Solid Cash Runway Support Buy Rating
7d ago
ELVN
Midday Fly By: Defense stocks surge on Trump budget request
PremiumThe Fly
Midday Fly By: Defense stocks surge on Trump budget request
8d ago
F
AA
Enliven reports ‘positive’ initial Phase 1b data for ELVN-001 in CML
PremiumThe Fly
Enliven reports ‘positive’ initial Phase 1b data for ELVN-001 in CML
8d ago
ELVN
Enliven announces expected 2026 clinical milestones for ELVN-001
PremiumThe Fly
Enliven announces expected 2026 clinical milestones for ELVN-001
8d ago
ELVN
Enliven Therapeutics appoints new board chair amid transition
PremiumCompany Announcements
Enliven Therapeutics appoints new board chair amid transition
9d ago
8K
ELVN
Enliven Therapeutics Appoints Richard Fair as CEO
PremiumCompany AnnouncementsEnliven Therapeutics Appoints Richard Fair as CEO
1M ago
8K
ELVN
Enliven announces the appointment of Fair as CEO
Premium
The Fly
Enliven announces the appointment of Fair as CEO
1M ago
ELVN
Enliven Therapeutics: Strategic Advancements and Promising Clinical Progress Support Buy Rating
Premium
Ratings
Enliven Therapeutics: Strategic Advancements and Promising Clinical Progress Support Buy Rating
2M ago
ELVN
Enliven Therapeutics: Promising Financial Discipline and Strategic Positioning Justify Buy Rating
PremiumRatings
Enliven Therapeutics: Promising Financial Discipline and Strategic Positioning Justify Buy Rating
2M ago
ELVN
Enliven Therapeutics Reports Q3 2025 Financial Results
PremiumCompany Announcements
Enliven Therapeutics Reports Q3 2025 Financial Results
2M ago
ELVN
Promising Future for Enliven Therapeutics: Buy Rating Backed by Strong Phase 1 Data and Financial Stability
PremiumRatings
Promising Future for Enliven Therapeutics: Buy Rating Backed by Strong Phase 1 Data and Financial Stability
2M ago
ELVN
Enliven reports Q3 EPS (32c) vs. (48c) last year
PremiumThe Fly
Enliven reports Q3 EPS (32c) vs. (48c) last year
2M ago
ELVN
Enliven Therapeutics: Strategic Positioning and Promising Data Justify Buy Rating
PremiumRatingsEnliven Therapeutics: Strategic Positioning and Promising Data Justify Buy Rating
2M ago
ELVN
Promising Investment Opportunity: Enliven Therapeutics’ ELVN-001 Shows Strong Potential in CML Treatment
Premium
Ratings
Promising Investment Opportunity: Enliven Therapeutics’ ELVN-001 Shows Strong Potential in CML Treatment
2M ago
ELVN
Enliven being 20% down on Terns news ‘makes no sense,’ says Mizuho
Premium
The Fly
Enliven being 20% down on Terns news ‘makes no sense,’ says Mizuho
2M ago
ELVN
TERN
Enliven Therapeutics Advances in CML Treatment with ELVN-001 Study
PremiumCompany Announcements
Enliven Therapeutics Advances in CML Treatment with ELVN-001 Study
3M ago
ELVN
Enliven Therapeutics’ ELVN-001: A Promising Phase 1 Study for Chronic Myeloid Leukemia
PremiumCompany Announcements
Enliven Therapeutics’ ELVN-001: A Promising Phase 1 Study for Chronic Myeloid Leukemia
3M ago
ELVN
Enliven, Novartis drugs poised to lead in CML markets, says Clear Street
PremiumThe Fly
Enliven, Novartis drugs poised to lead in CML markets, says Clear Street
3M ago
NVS
ELVN
Enliven Therapeutics: Strong Buy Rating Backed by Promising Clinical Results and Robust Financial Position
PremiumRatings
Enliven Therapeutics: Strong Buy Rating Backed by Promising Clinical Results and Robust Financial Position
5M ago
ELVN
Enliven Therapeutics: Strong Financial Foundation and Promising ELVN-001 Development Justify Buy Rating
PremiumRatingsEnliven Therapeutics: Strong Financial Foundation and Promising ELVN-001 Development Justify Buy Rating
5M ago
ELVN
Enliven Therapeutics: Strong Financial Health and Promising CML Treatment Drive Buy Rating
Premium
Ratings
Enliven Therapeutics: Strong Financial Health and Promising CML Treatment Drive Buy Rating
5M ago
ELVN
Enliven Therapeutics Reports Positive Trial Results and Strong Financials
Premium
Company Announcements
Enliven Therapeutics Reports Positive Trial Results and Strong Financials
5M ago
ELVN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >